Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...

Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

Type 1 diabetes is a disease where the immune system destroys insulin-producing beta cells in pancreatic islets. About 2 million Americans have Type 1 diabetes. The islets of Langerhans are named for ...

Each Sunday we feature a highlight reel of various articles posted on our website that week.

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

However, one significant problem has proven surprisingly durable: misdiagnosis of Type 1 diabetes (T1D). Estimates suggest ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

Independent practices face challenges from consolidation and policy shifts, with hybrid models offering autonomy while sharing financial risk. Value-based care in oncology prioritizes science, ...

The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders. Instead, they suggest that internal ...